| |
Transform the Industry with Your Innovation! Submissions are now open for the Fierce Life Sciences Innovation Awards. Click to submit your entry and learn more about the categories and criteria.
|
|
Today’s Big NewsAug 1, 2024 |
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Save up to $500 with Early Bird Rates. Register Now!
|
|
| By Zoey Becker The ruling from the New Jersey federal court marks the latest in a string of rejections as various drugmakers have taken to the courts to fight the drug pricing legislation. |
|
|
|
By Annalee Armstrong While Biogen’s pharma peers are hunting for late-stage assets with little risk, CEO Chris Viehbacher wants to bring in more early-stage medicines, arguing that there’s more shareholder value to be had the earlier a company can get in. |
By Annalee Armstrong Biogen has handed back rights to an early Alzheimer’s disease program to Denali Therapeutics, leaving a large hole in the biotech’s collaboration revenue stream. |
By Conor Hale “We believe that no other company in medtech is better positioned than BD to capitalize on this trend,” CEO Tom Polen said on the company's second-quarter earnings call. |
|
Sept. 25 - 26, 2024 | San Diego, CA Cutting-edge educational sessions: Gain insights from industry leaders. Early Bird Rate ends August 2nd, Save $400, Register Today!
|
|
By Eric Sagonowsky After two quarters, Moderna is chopping $500 million to $1 billion from its prior revenue forecast for the year. The company attributed several challenges with its marketing of COVID-19 vaccine Spikevax for the adjustment. |
By Kevin Dunleavy Four months after Bayer handed pink slips to 90 staffers at its U.S. headquarters in Whippany, New Jersey, the company is laying off 70 more at the site, according to a state Worker Adjustment and Retraining Notification. |
By Gabrielle Masson As biotechs attempt to turn a fresh page in August, at least three companies have shed staff in attempts to forge on. |
By Kevin Dunleavy The launch of Regeneron's Eylea HD has helped the Eylea franchise to a rebound after U.S. sales had declined in each of the previous three quarters. Additionally, Regeneron reported that its FDA decision date on its application for approval of multiple myeloma therapy linvoseltamab is likely to be delayed because of a manufacturing issue. The target date is August 22. |
By Conor Hale Aimed at oncology researchers and the makers of cancer drugs and diagnostics, the pair of foundation models were developed through a collaboration with Microsoft Research. |
By Darren Incorvaia Veteran venture capital firm venBio has raised another half billion dollars to invest in biotechs working on diseases with unmet need. |
By Angus Liu Kyowa Kirin is planning “a significant reduction” in its small molecule drug discovery research activities and will trim certain manufacturing roles. The company is also divesting its Chinese operations as part of a larger restructuring in the Asia-Pacific region. |
Fierce podcastsDon’t miss an episode |
| | This week on "Podnosis," we dive into the topic of how to improve diversity and equity in dermatology. |
|
|---|
|
|
|
Wednesday, September 11, 2024 | 2pm ET / 11am PT As the drug development landscape rapidly evolves, artificial intelligence (AI) is emerging as a transformative force, fundamentally reshaping processes and enhancing efficiencies. Join us for a deep dive into AI’s significant impact on streamlining clinical project management, revolutionizing the generation of crucial research outputs and accelerating drug discovery. Register now.
|
|
| WhitepaperThis paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
| WhitepaperDownload the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
| WhitepaperIn this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
| WhitepaperIn a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
